| Literature DB >> 27983937 |
Xiangfei He1, Fuguang Sun, Fengfu Guo, Kai Wang, Yisheng Gao, Yanfei Feng, Bin Song, Wenzhi Li, Yang Li.
Abstract
Renal cell carcinoma (RCC) is one of the most common kidney cancers worldwide. Although great progressions have been made in the past decades, its morbidity and lethality remain increasing. Long noncoding RNAs (lncRNAs) are demonstrated to play significant roles in the tumorigenesis. This study aimed to investigate the detailed roles of lncRNA FTX in RCC cell proliferation and metastasis. Our results showed that the transcript levels of FTX in both clinical RCC tissues and the cultured RCC cells were significantly upregulated and associated with multiple clinical parameters of RCC patients, including familial status, tumor sizes, lymphatic metastasis, and TNM stages. With cell proliferation assays, colony formation assays, and cell cycle assays, we testified that knockdown of FTX in A498 and ACHIN cells with specific shRNAs inhibited cell proliferation rate, colony formation ability, and arrested cell cycle in the G0/G1 phase. FTX depletion also suppressed cell migration and invasion with Transwell assays and wound-healing assays. These data indicated the pro-oncogenic potential of FTX in RCC, which makes it a latent therapeutic target of RCC diagnosis and treatment in the clinic.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27983937 PMCID: PMC7840817 DOI: 10.3727/096504016X14719078133203
Source DB: PubMed Journal: Oncol Res ISSN: 0965-0407 Impact factor: 5.574
Figure 1Long noncoding RNA FTX was overexpressed in human renal cell carcinoma (RCC) tissues and cells. (A) Total RNAs were extracted from 150 clinical RCC tissues and their adjacent noncancerous tissues and subjected to real-time polymerase chain reaction (RT-PCR) analysis. The transcript level of FTX in the tumor tissues was fourfold higher than that in their noncancerous counterparts. *p < 0.05 versus Adjacent. (B) Five RCC cell lines and a control renal cell line HKC were included to assess the expression of FTX in RCC cells by RT-PCR assays. A498 and ACHIN showed the highest transcript levels of FTX, while other RCC cells also presented higher FTX expressions compared with HKC cells. *p < 0.05 versus HKC cells.
The Correlations Between the Transcript Level of FTX and the Clinical Parameters of RCC Patients
| Clinical Parameters | Cases | Transcript Level of FTX |
| |
|---|---|---|---|---|
| High ( | Low ( | |||
| Ages (years) | 0.092 | |||
| <65 | 99 | 59 | 40 | |
| ≥65 | 51 | 23 | 28 | |
| Gender | 0.669 | |||
| Male | 79 | 42 | 37 | |
| Female | 76 | 40 | 31 | |
| Marital status | 0.362 | |||
| Single | 10 | 4 | 6 | |
| Married | 99 | 54 | 45 | |
| Separated | 41 | 24 | 17 | |
| Familial status | <0.001 | |||
| Sporadic | 109 | 44 | 65 | |
| Familial | 41 | 38 | 3 | |
| Tumor size (cm) | <0.001 | |||
| ≤4 | 26 | 6 | 20 | |
| 4–7 | 44 | 18 | 26 | |
| ≥7 | 80 | 58 | 22 | |
| Lymph node | 0.062 | |||
| N0 | 54 | 35 | 19 | |
| N1 | 96 | 47 | 49 | |
| Lymphatic metastasis | <0.001 | |||
| Absence | 57 | 19 | 38 | |
| Presence | 93 | 63 | 30 | |
| TNM stage | <0.001 | |||
| I–II | 51 | 17 | 34 | |
| III–IV | 99 | 65 | 34 | |
Figure 2Knockdown of FTX inhibited cell proliferation in RCC cells. (A) Two specific shRNAs were designed and transfected into A498 and ACHIN cells. The transcript level of FTX was significantly decreased by shFTX-1 in both cell lines; however, only little decline was observed by shFTX-2 transfection. *p < 0.05 versus Control in A498 cells. #p < 0.05 versus Control in ACHIN cells. (B) Transfection of shFTX suppressed cell proliferation rate in A498 cells on the fourth and fifth days. (C) Transfection of shFTX suppressed cell proliferation rate in ACHIN cells on the fourth and fifth days. *p < 0.05 versus Control.
Figure 3Knockdown of FTX inhibited colony formation and arrested cell cycle in the G0/G1 phase in RCC cells. (A) Colony formation assays showed that knockdown of FTX with specific shRNA inhibited the cell ability to form colonies in both A498 and ACHIN cells. *p < 0.05 versus Control in A498 cells. #p < 0.05 versus Control in ACHIN cells. (B) shFTX treatment in A498 cells shifted cell cycle from the S phase and G2/M phase to the G0/G1 phase. (C) Transfection of shFTX in ACHIN cells arrested cell cycle in the G0/G1 phase. *p < 0.05 versus Control.
Figure 4Knockdown of FTX suppressed cell migration and invasion in RCC cells by Transwell assay. (A) Representative images of cells migrated through the membrane and stained on the lower surface of the membrane in A498 and ACHIN cells. (B) Quantification of cell migration assays revealed FTX depletion with shFTX inhibited the cell migration ability in A498 and ACHIN cells. *p < 0.05 versus Control in A498 cells. #p < 0.05 versus Control in ACHIN cells. (C) Representative images of cells that invaded through the membrane in A498 and ACHIN cells. (D) Quantification of cell invasion assays revealed FTX depletion with shFTX inhibited cell invasion ability in A498 and ACHIN cells. *p < 0.05 versus Control in A498 cells. #p < 0.05 versus Control in ACHIN cells.
Figure 5Knockdown of FTX suppressed cell migration and invasion in RCC cells by wound-healing assay. (A) Representative images of wound-healing assays in A498 cells. The pictures were captured 24 h posttransfection. (B) Quantification of wound-healing assay for A498 cells showed that more than 60% cells were retarded to migrate upon shFTX transfection. (C) Representative images of wound-healing assays in ACHIN cells. (D) Quantification of wound-healing assay suggested that more than 60% ACHIN cells were suppressed to migrate upon shFTX transfection. *p < 0.05 versus Control.